Kayne Anderson Rudnick Investment Management
COGT icon

Kayne Anderson Rudnick Investment Management’s Cogent Biosciences COGT Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-139
Closed -$1K – 617
2022
Q1 		$1K Buy
+139
New +$968 ﹤0.01% 623

Other funds holding COGT

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's COGT Position: Q2 2022 in Review

Kayne Anderson Rudnick Investment Management sold out of Cogent Biosciences (COGT) in Q2 2022, closing a stake of 139 shares — an estimated $1K sold.

Kayne Anderson Rudnick Investment Management first reported a position in COGT in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 112 funds tracked by Wall St. Rank hold COGT as of Q2 2022.

  • Kayne Anderson Rudnick Investment Management reported no remaining Cogent Biosciences position as of Q2 2022 after selling out during the quarter.
  • Kayne Anderson Rudnick Investment Management sold 139 Cogent Biosciences shares in Q2 2022, an estimated $1K.
  • Kayne Anderson Rudnick Investment Management first reported a position in Cogent Biosciences in Q1 2022 and held it in 1 quarter.
  • Kayne Anderson Rudnick Investment Management's Cogent Biosciences position peaked at $1K in Q1 2022.
  • 112 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2022.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q2 2022, filed 12 Aug 2022.